


PHARMACEUTICAL 2018

ZOGENIX INC. Rank 26 of 342







PHARMACEUTICAL 2018



ZOGENIX INC. Rank 26 of 342

The relative strengths and weaknesses of ZOGENIX INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ZOGENIX INC. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 47% points. The greatest weakness of ZOGENIX INC. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 253%, being 208% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	304,703
Cost of Goods Sold	0
Intangible Assets	6,234
Liabilities, Current	20,983
Liabilities, Non-Current	0
Other Assets	106,431
Other Compr. Net Income	0
Other Expenses	36,423
Other Liabilities	0
Other Net Income	-6,881
Other Revenues	9,821
Property and Equipment	245
Research and Development	67,449
Selling, General and Administrative Expense	25,885

Output Variable	Value in 1000 USD
Assets	417,613
Liabilities	20,983
Expenses	129,757
Revenues	9,821
Stockholders Equity	396,630
Net Income	-126,817
Comprehensive Net Income	-126,817
Economic Capital Ratio	253%

